| P/E (FY) | 14.6 | Sales (TTM) | $509.9M |
| Earnings (TTM) | $165.4M | ROE | 35.56% |
| Net Margin | 28.80% | ROIC | 39.48% |
| Debt / Equity | 0.15 | TD / EBITDA | 0.36 |
| EPS Growth 3Y | — | Sales Growth 3Y | 49.05% |
ADMA Biologics is a biopharmaceutical company that develops, manufactures, and markets specialty plasma-derived biologics for immune deficiencies and infectious diseases in the United States and internationally. It operates through ADMA BioManufacturing and Plasma Collection Centers segments. Products include BIVIGAM and ASCENIV, intravenous immune globulin products for primary humoral immunodeficiency, and Nabi-HB, a polyclonal antibody for acute Hepatitis B exposure. The company also develops a pipeline of plasma-derived therapeutics.
| Market Cap | $2.04B | Trading Days | 3209 |
| 52W High | 20.46 |
| 52W Low | 7.21 |
| % Off High | −57.03% |
| YTD | −51.81% | 1Y | −51.17% |
| 3Y | 118.11% | 5Y | 449.37% |
| 10Y | 20.25% | Since incept. (ann.) | 0.22% |
ADMABio Manufacturing 97% · Plasma Collection Centers 3%
| Ann. Volatility (1Y) | 54.37% | Ann. Volatility (3Y) | 57.36% |
| Sharpe (1Y) | −1.06 | Sharpe (3Y) | 0.76 |
| Max Drawdown (1Y) | −62.71% | Max Drawdown (3Y) | −68.99% |
| Beta (3Y, vs SPY) | 1.35 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| IOVA | IOVANCE BIOTHERAPEUTICS, INC. | $2.10B | — |
| GLUE | Monte Rosa Therapeutics, Inc. | $1.86B | — |
| COAG | Hemab Therapeutics Holdings, Inc. | $2.35B | — |
| VCEL | Vericel Corp | $2.39B | 146.0 |
| IMCR | Immunocore Holdings plc | $1.70B | — |
| BCRX | BIOCRYST PHARMACEUTICALS INC | $2.48B | 8.0 |
| KOD | Kodiak Sciences Inc. | $2.52B | — |
| TARS | Tarsus Pharmaceuticals, Inc. | $2.54B | — |
| TSHA | Taysha Gene Therapies, Inc. | $1.57B | — |
| MAZE | Maze Therapeutics, Inc. | $1.54B | — |
| BEAM | Beam Therapeutics Inc. |
| $2.70B |
| — |
| VIR | Vir Biotechnology, Inc. | $1.49B | — |
